Rapid Mycoplasma Testing vs Traditional Methods: Which Is Better for ATMPs?
Advanced Therapy Medicinal Products (ATMPs) are transforming modern healthcare through innovative treatments such as cell therapies, gene therapies, and tissue-engineered products. As these therapies move toward commercialization, maintaining strict quality and safety standards becomes increasingly important. One of the biggest concerns in ATMP manufacturing is microbial contamination, especially mycoplasma contamination, which can compromise product quality, patient safety, and regulatory compliance. Because of this risk, reliable mycoplasma detection and robust sterility testing strategies are essential throughout the manufacturing process. However, manufacturers often face a critical question: should they rely on traditional testing methods or adopt rapid mycoplasma testing technologies? Understanding the Risk of Mycoplasma Contamination Mycoplasmas are small bacteria that lack a cell wall, making them difficult to identify through standard microscopy. They can spread quickly in ce...